The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Open accessAbstract
BACKGROUND: Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy. METHODS: This double-blind study compared the effect of palifermin with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous hematopoietic stem-cell transplantation. Oral mucositis was evaluated daily for 28 days after transplantation. RESULTS: The incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4 was 63 percent in the palifermin group and 98 percent in the placebo group (P<0.001). Among patients with this degree of mucositis, the median duration of mucositis was 6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the placebo group. Among all patients, regardless of the occurrence of mucositis, the median duration of oral mucositis of WHO grade 3 or 4 was 3 days (range, 0 to 22) in the palifermin group and 9 days (range, 0 to 27) in the placebo group (P<0.001). As compared with placebo, palifermin was associated with significant reductions in the incidence of grade 4 oral mucositis (20 percent vs. 62 percent, P<0.001), patient-reported soreness of the mouth and throat (area-under-the-curve score, 29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418], P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P<0.001). Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration, were mild to moderate in severity and were transient. CONCLUSIONS: Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Purification and characterization of a newly identified growth factor specific for epithelial cells.
Rubin, J. S., Osada, H., Finch, P. W., Taylor, W. G., Rudikoff, S., & Aaronson, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.3.802 · Cited by 833
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
Sonis, S. T., Oster, G., Fuchs, H., Bellm, L., Bradford, W. Z., Edelsberg, J., Hayden, V., Eilers, J., Epstein, J. B., LeVeque, F. G., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2201 · Cited by 678
Sonis, S. T. (1998) · Oral Oncology · doi:10.1016/s1368-8375(97)00053-5 · Cited by 565
Landis, J. R., Heyman, E. R., & Koch, G. G. (1978) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402373 · Cited by 454
Patient reports of complications of bone marrow transplantation
Bellm, L. A., Epstein, J. B., Rose-Ped, A., Martin, P., & Fuchs, H. J. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900095 · Cited by 366
Farrell, C. L., Bready, J. V., Rex, K. L., Chen, J. N., DiPalma, C., Whitcomb, K. L., Yin, S., Hill, D. C., Wiemann, B., Starnes, C. O., et al. (1998) · PubMed · Cited by 357
McGuire, D. B., Altomonte, V., Peterson, D., Wingard, J. R., Jones, R., & Grochow, L. B. (1993) · PubMed · Cited by 160
Cited by
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., McGuire, D. B., Migliorati, C., Nicolatou‐Galitis, O., Peterson, D. E., et al. (2014) · Cancer · doi:10.1002/cncr.28592 · Cited by 1,110
Updated clinical practice guidelines for the prevention and treatment of mucositis
Keefe, D. M., Schubert, M. M., Elting, L. S., Sonis, S. T., Epstein, J. B., Raber‐Durlacher, J. E., Migliorati, C. A., McGuire, D. B., Hutchins, R. D., & Peterson, D. E. (2007) · Cancer · doi:10.1002/cncr.22484 · Cited by 784
Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration
Yun, Y.-R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J.-H., Shin, U. S., & Kim, H.-W. (2010) · Journal of Tissue Engineering · doi:10.4061/2010/218142 · Cited by 712
Interventions for treating oral mucositis for patients with cancer receiving treatment
Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., & Meyer, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001973.pub4 · Cited by 674
Management of Oral Mucositis in Patients Who Have Cancer
Lalla, R. V., Sonis, S. T., & Peterson, D. E. (2008) · Dental Clinics of North America · doi:10.1016/j.cden.2007.10.002 · Cited by 602
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Self-citationElting, L. S., Cooksley, C. D., Chambers, M. S., & Garden, A. S. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.053 · Cited by 533
Mucositis: The impact, biology and therapeutic opportunities of oral mucositis
Sonis, S. T. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.08.006 · Cited by 525
Radioprotectors and mitigators of radiation-induced normal tissue injury
Citrin, D., Cotrim, A. P., Hyodo, F., Baum, B. J., Krishna, M. C., & Mitchell, J. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-s104 · Cited by 482
Oral mucositis: the hidden side of cancer therapy
Pulito, C., Cristaudo, A., Porta, C. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01715-7 · Cited by 468
Oral complications of radiotherapy
Sciubba, J. J., & Goldenberg, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70580-0 · Cited by 358
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
Cinausero, M., Aprile, G., Ermacora, P., Basile, D., Vitale, M. G., Fanotto, V., Parisi, G., Calvetti, L., & Sonis, S. T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00354 · Cited by 290
Skin regeneration scaffolds: a multimodal bottom-up approach
Yildirimer, L., Thanh, N. T. K., & Seifalian, A. M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.08.004 · Cited by 286
Logan, R. M., Stringer, A. M., Bowen, J. M., Yeoh, A. S.-J., Gibson, R. J., Sonis, S. T., & Keefe, D. M. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.03.001 · Cited by 279
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A.-M., Littlewood, A., McCabe, M. G., Meyer, S., Khalid, T., & Riley, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000978.pub5 · Cited by 262
History and development of radiation-protective agents
Weiss, J. F., & Landauer, M. R. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000902985144 · Cited by 258
Scully, C., Sonis, S., & Diz, P. (2006) · Oral Diseases · doi:10.1111/j.1601-0825.2006.01258.x · Cited by 253
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Teven, C. M., Farina, E. M., Rivas, J., & Reid, R. R. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.09.005 · Cited by 237
Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration.
Alpdogan, O., Hubbard, V. M., Smith, O. M., Patel, N., Lu, S., Goldberg, G. L., Gray, D. H., Feinman, J., Kochman, A. A., Eng, J. M., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2831 · Cited by 220
Min, D., Panoskaltsis-Mortari, A., Kuro-o, M., Holländer, G. A., Blazar, B. R., & Weinberg, K. I. (2007) · Blood · doi:10.1182/blood-2006-08-043794 · Cited by 214
Self-citationEcdysterone Attenuates the Development of Radiation-Induced Oral Mucositis in Rats at Early Stage
Yang, L., Friedemann, T., & Pan, J. (2021) · Radiation Research · doi:10.1667/rade-21-00042.1 · Cited by 5
Metadata
- Authors
- Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, C. F., Sung, E. C., Blazar, B. R., Elhardt, D., Chen, M.-G., & Emmanouilides, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-16
- Volume
- 351
- Issue
- 25
- Pages
- 2590-2598
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160115655
- Cited by
- 893
- References
- 13
- FWCI
- 55.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.